Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 166 results for "wallachbeth capital llc"

WallachBeth Capital Upgrades VIVUS to Buy (VVUS)

WallachBeth Capital Upgrades VIVUS to Buy (VVUS)

VIVUS (NASDAQ:VVUS) was upgraded by WallachBeth Capital from a hold rating to a buy rating in a research note issued on Thursday, ARN reports. The firm currently has a $2.80 price objective on the biopharmaceutical company's stock, up from their ... WKRB News, 2 weeks ago

Esperion Therapeutics Coverage Initiated at WallachBeth Capital (ESPR)

Tweet [embedded content] Research analysts at WallachBeth Capital initiated coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Monday, The Fly reports. The brokerage set a buy rating and a $34.00 price ...
 Zolmax News3 weeks ago Esperion Therapeutics Receives New Coverage from Analysts at Lake Street Capital (ESPR)  SleekMoney4 weeks ago How Will Esperion Therapeutics (NASDAQ:ESPR) Stock React To WallachBeth New Ratings Coverage and $34.00 TP?  Octafinance4 weeks ago

Arena Pharmaceuticals Stock Rating Reaffirmed by Needham & Company LLC (ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA)s stock had its hold rating restated by research analysts at Needham & Company LLC in a research report issued on Friday, MarketBeat Ratings reports. Other research analysts have also issued research reports ...
 American Banking News - Forex3 weeks ago WallachBeth Maintains a Buy Rating on Arena Pharmaceuticals (NASDAQ:ARNA) and $4.00 Target  Octafinance3 weeks ago Sucampo Pharmaceuticals Receives $24.00 Consensus Target Price from Analysts (NASDAQ:SCMP)  WKRB News3 days ago Arena Pharmaceuticals Given Consensus Recommendation of Buy by Brokerages (NASDAQ:ARNA)  American Banking News6 days ago

Roth Capital Reduces Q1 2016 EPS Estimates for Sucampo Pharmaceuticals (SCMP)

[embedded content] Equities researchers at Roth Capital dropped their Q1 2016 EPS estimates for shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a note issued to investors on Thursday, Zacks Investment Research reports. Roth Capital analyst M.
 Zolmax News2 weeks ago Roth Capital Issues Q4 2015 Earnings Estimate for Sucampo Pharmaceuticals (SCMP)  SleekMoney2 weeks ago Roth Capital Research Analysts Lowers Earnings Estimates for Sucampo Pharmaceuticals (SCMP)  SleekMoney2 weeks ago Roth Capital Issues FY2015 Earnings Estimate for Sucampo Pharmaceuticals (SCMP)  American Banking News2 weeks ago

Clovis Oncology Inc (NASDAQ:CLVS) Given a Hold Rating at WallachBeth. Lost Its Buy Rating

Clovis Oncology Inc (NASDAQ:CLVS) Rating Change Clovis Oncology Inc (NASDAQ:CLVS)'s Buy rating is no longer valid. stock analysts at WallachBeth decreased Clovis Oncology Inc (NASDAQ:CLVS)'s rating to Hold. The stock downgrade was noticed by ...
 Octafinance1 week ago Why Clovis Oncology Inc Is Falling Again  Nasdaq1 week ago Hedge Funds Are Crazy For Clovis Oncology Inc (NASDAQ:CLVS)  Octafinance2 weeks ago

Arena Pharmaceuticals PT Lowered to $2.00 at RBC Capital (ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) had its price objective reduced by RBC Capital from $5.00 to $2.00 in a research report sent to investors on Wednesday, MarketBeat.Com reports. RBC Capital currently has a sector perform rating on the ...
 WKRB News1 week ago

Needham & Company LLC Reiterates Positive Rating for Esperion Therapeutics (ESPR)

Esperion Therapeutics (NASDAQ:ESPR)s stock had its positive rating reiterated by research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday, reports. A number of other ...
 American Banking News - Forex2 weeks ago Esperion Therapeutics Earns Positive Rating from Needham & Company LLC (ESPR)  American Banking News - Forex2 weeks ago

DepoMed (NASDAQ:DEPO) Increased to Buy Rating With $33.0 Target Price by Analysts at WallachBeth from Hold Rating

DepoMed (NASDAQ:DEPO) Rating Improved WallachBeth raised the shares of DepoMed (NASDAQ:DEPO) from a Hold rating to Buy rating in a report sent to clients and investors on Wednesday morning. The broker from today has $33.0 target on the stock. ...
 Octafinance2 weeks ago CTI BioPharma (NASDAQ:CTIC) Downgraded to Hold Rating With $1.6 Target Price per Share by WallachBeth from Buy Rating  Octafinance2 weeks ago
Ticker Report

Arena Pharmaceuticals (ARNA) Research Analysts Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Arena Pharmaceuticals (NASDAQ: ARNA) in the last few weeks: 11/13/2015 Arena Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a hold ...
 American Banking News - Forex1 day ago Research Analysts Recent Ratings Changes for Arena Pharmaceuticals (ARNA)  American Banking News - Forex2 weeks ago Esperion Therapeutics (ESPR) Analysts Recent Ratings Updates  American Banking News2 weeks ago Weekly Analysts Ratings Updates for Arena Pharmaceuticals (ARNA)  American Banking News - Forex3 weeks ago

Esperion Therapeutics Inc (NASDAQ:ESPR) Hedge Funds Sentiment Increased in Q2 2015

Esperion Therapeutics Inc (NASDAQ:ESPR) Sentiment Esperion Therapeutics Inc (NASDAQ:ESPR) hedge funds sentiment decreased to 1.77 in Q2 2015 . Its down -1.48, from 3.25 in 2015Q1. The sentiment fall, as 110 hedge funds increased and opened new ...
 Octafinance3 days ago Is Esperion Therapeutics Inc (NASDAQ:ESPR) Going to Burn These Hedge Funds?  Octafinance3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - wallachbeth capital llc
Get updated on latest news & your favorite topics right in your inbox!
More     Less